<DOC>
	<DOC>NCT00546754</DOC>
	<brief_summary>To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.</brief_summary>
	<brief_title>BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>An Adult Patient 18 to 75 Years Of Age Patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can (and will) be discontinued and whose blood pressure is not controlled: Either systolic or diastolic blood pressure &gt; 140/90 mm Hg up to 180/110 mm Hg (inclusive) Either systolic or diastolic blood pressure &gt; 130/80 mm Hg up to 160/100 mm Hg (inclusive) for diabetic patients Patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below: Surgically sterilized female Postmenopausal female &gt; 45 years of age with &gt; 2 years since her last menses Nonsterilized premenopausal female who agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy [either 2 barrier methods or a barrier method plus a hormonal method]; or (2) abstain from heterosexual activity throughout the study starting with Visit 1 and for 14 days after the last dose of study medication; or (3) only engage in heterosexual activity with surgically sterilized male partner(s) throughout the study starting with Visit 1 and for 14 days after the last dose of study medication Patient judged to be in otherwise good, stable health on the basis of medical history and physical examination Known secondary hypertension of any aetiology (e.g., uncorrected renal artery stenosis, malignant hypertension, or hypertensive encephalopathy) Patient Needing An Initiation Of A Lipid Lowering Agent Or A Modification Of His Lipid Therapy At Visit 1 Or During The Study Period (12 Weeks) Patient taking allopurinol Patient Previously Shown To Be Intolerant To Any Component Of Losartan Valsartan, Or HCTZ Or With A Documented History Of Angioedema/Anaphylaxis Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or Electrolyte Imbalance Laboratory Test Within The Last 3 Months Prior To Visit 1: Serum Creatinine &gt; 130 Umol/L Or Creatinine Clearance &lt; 45 Ml/Min, Aspartate transaminase (AST) &gt; 2 Times Above The Normal Range, Alanine transaminase (ALT) &gt; 2 Times Above The Normal Range, Serum Potassium &lt; 3.5 Or &gt; 5.5 Meq/L Patient with osteoarthritis who has undergone hip or knee replacement within the last 4 months Patient with chronic inflammatory conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents Patient with symptomatic heart failure (classes 3 and 4) Patient with a history of stroke within the last 6 months Patient with coronary heart disease: has undergone percutaneous coronary angioplasty, has had coronary artery bypass, has had past myocardial infarction, all that occurred less than 6 months prior to visit 1 or has unstable angina Patient having participated in an investigational drug program in the last 30 days (prior to Visit 1) Unable or unwilling to comply with the protocol, therefore likely to leave the trial before its completion Patient intends to move or to vacation away from home during the course of the study which would interfere with the scheduled visits.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>